Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Antibody detection assays are essential for evaluating immunity of individuals against a given virus, and this has been particularly relevant during the COVID-19 pandemic. Current serology assays either require a laboratory setting and take >1 hr (i.e., enzyme-linked immunosorbent assay [ELISA]) or are rapid but only qualitative in nature and cannot accurately track antibody levels over time (i.e., lateral flow assay [LFA]). Therefore, there is a need for development of a rapid and simple but also quantitative assay that can evaluate antibody levels in patients accurately over time. We have developed an assay that uses a split nanoluciferase fused to the spike or nucleocapsid proteins of the SARS-CoV-2 virus to enable luminescent-based detection of spike- or nucleocapsid-binding antibodies in serum, plasma, and whole blood samples. The resulting approach is simple, rapid, and quantitative and is highly amenable to low-/medium-throughput scale using plate-based assays, high-throughput scale using robotics, and point-of-care applications. In this article, we describe how to perform the assay in a laboratory setting using a plate reader or liquid-handling robotics and in a point-of-care setting using a handheld, battery-powered luminometer. Together, these assays allow antibody detection to be easily performed in multiple settings by simplifying and reducing assay time in a laboratory or clinical environment and by allowing for antibody detection in point-of-care, nonlaboratory settings. © 2022 Wiley Periodicals LLC. Basic Protocol: SARS-CoV-2 antibody detection using the split-luciferase assay on a medium-throughput scale with a laboratory luminometer Alternate Protocol 1: High-throughput-based protocol for SARS-CoV-2 antibody detection using a robotic platform Alternate Protocol 2: Point-of-care-based protocol for SARS-CoV-2 antibody detection using a handheld luminometer Support Protocol: Determining positive/negative cutoffs for test samples and standardizing the assay between days.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793882PMC
http://dx.doi.org/10.1002/cpz1.521DOI Listing

Publication Analysis

Top Keywords

antibody detection
28
sars-cov-2 antibody
16
protocol sars-cov-2
12
antibody
9
detection
8
serum plasma
8
plasma blood
8
blood samples
8
laboratory setting
8
assay
8

Similar Publications

Recent progress of rapid detection technologies for mycotoxins.

Food Chem

September 2025

International Joint Research Laboratory for Biointerface and Biodetection, and School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, PR China. Electronic address:

Mycotoxins, due to their high carcinogenic and genotoxic properties, pose a significant threat to global food safety. Traditional detection methods often fall short in meeting the demands for large-scale, real-time, simple, and rapid monitoring. As a result, innovative rapid detection approaches, leveraging advanced materials and sensor technologies, are emerging as key solutions for preventing food contamination.

View Article and Find Full Text PDF

Clinical, virological, and antibody profiles of overlapping dengue and chikungunya virus infections in children from southern Colombia.

PLoS Negl Trop Dis

September 2025

División de Inmunología, Programa de Medicina, Facultad de Ciencias de la Salud, Universidad Surcolombiana, Neiva, Huila, Colombia.

Background: Dengue and chikungunya are arboviral diseases with overlapping clinical characteristics. Dengue virus (DENV) is endemic in Colombia, and in 2014/2015, the chikungunya virus (CHIKV) caused an epidemic that resulted in over 350,000 cases. Since then, both viruses have been actively co-circulating.

View Article and Find Full Text PDF

Immunogenicity comparison of an -produced 9-valent human papillomavirus vaccine and Gardasil9 in Chinese women aged 18-26 years: three-year follow-up data from a randomised clinical trial.

Lancet Reg Health West Pac

September 2025

State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, China.

Background: Cecolin9, a second-generation 9-valent HPV vaccine derived from the WHO-prequalified Cecolin, has received marketing authorisation in China in May 2025. The non-inferiority of type-specific immune responses between Cecolin9 and Gardasil9 has been previously established at month 7 in Chinese women aged 18-26 years (NCT04782895). This study aimed to compare the plateau antibody levels between the two vaccines three years post the first dose.

View Article and Find Full Text PDF

Background: Dyspnea is a common clinical symptom and cause of outpatient and inpatient presentations to the clinic. Diagnostic and therapeutic challenges appear, when additional diseases appear that are themselves associated with subjectively perceptible dyspnea. We report on a young woman with orthopnea as a trigger of a diagnostic cascade of various diseases.

View Article and Find Full Text PDF

Toxocariasis, a neglected zoonotic disease caused by parasites of the genus, represents a significant public health concern, with an estimated global seroprevalence of 19%. Despite the well-known respiratory symptoms associated with toxocariasis, the immune response in the lungs during toxocariasis is still poorly understood. This study analyzes both local lung and systemic immune response to infection and excretory-secretory antigens (TES) intranasal application in C57BL/6J mice.

View Article and Find Full Text PDF